Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Biome Australia Ltd ( (AU:BIO) ).
Biome Australia Limited has announced the appointment of Geoff Sam as the new Chairman of the Board of Directors, following the resignation of Ilario Faenza. Geoff Sam, who brings significant expertise in healthcare and pharmaceutical manufacturing, is expected to play a crucial role in guiding Biome through its Vision 27 strategic plan and optimizing manufacturing processes. His leadership is anticipated to support the ongoing commercial development of Biome’s products both locally and internationally, aligning with the company’s growth objectives.
The most recent analyst rating on (AU:BIO) stock is a Buy with a A$0.85 price target. To see the full list of analyst forecasts on Biome Australia Ltd stock, see the AU:BIO Stock Forecast page.
More about Biome Australia Ltd
Biome Australia Limited is a company that develops, licenses, commercializes, and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines. These products, supported by clinical research, aim to improve health outcomes and quality of life. Incorporated in Australia in 2018, Biome distributes its products locally and internationally, partnering with leading organizations in microbiome research to produce unique probiotic products with advanced delivery technologies.
Average Trading Volume: 233,157
Technical Sentiment Signal: Sell
For detailed information about BIO stock, go to TipRanks’ Stock Analysis page.